Pharmaceutical - Xofigo, Markets & Marketing

Filter

Current filters:

XofigoMarkets & Marketing

Popular Filters

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

Prostate cancer market to almost double to $8 billion by 2019, says GBI

21-11-2013

The prostate cancer treatment market is forecast to increase from $4.1 billion in 2012 to $8 billion…

Active BiotechAstellas PharmaJohnson & JohnsonMarkets & MarketingOncoGenexOncologyPharmaceuticalTeva Pharmaceutical IndustriesXofigoXtandiZytiga

First sales of Xofigo triggers 50 million-euro milestone payment to Algeta from Bayer

30-05-2013

Norway's Algeta (OSE: ALGETA) announced today (May 30) that Xofigo (radium Ra 223 dichloride) injection…

AlgetaBayerFinancialMarkets & MarketingNorth AmericaPharmaceuticalXofigo

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top